Intraperitoneal Injection Bevacizumab Combined With Hyperthermic Intraperitoneal Chemotherapy In Treatment Of Ovarian Cancer:a Meta-analysis

Objective: To evaluation the clinical safety and effectiveness of Intraperitoneal injection bevacizumab combined with Hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer and explore the value of its clinical use.Methods: The database such as Medline,PubMed,Cochrane Library,EMbase,Web of Science,CNKI,CBM,VIP and WanFang Data were searched for randomized controlled trial(RCT)that of Intraperitoneal injection bevacizumab combined with Hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer from inception to Feb.2017.And relevant magazine were also selected.Two reviewers independently screened literature according to the inclusion and exclusion criteria as well as the methods recommended by the Cochrane Handbook 5.0.1,extracted efficient data and assessed the methodological quality of the included studies.Then,the meta-analyses were performed using RevMan 5.3 software.Results: A total of 8 RCTs were included for this meta-analysis.Meta analysis showed that,comparing with Hyperthermic intraperitoneal chemotherapy group,The short-term curative effect of Intraperitoneal injection bevacizumab combined with Hyperthermic intraperitoneal chemotherapy were significant higher,the difference was significant [OR= 3.83,95%CI(2.47~5.94),P<0.00001].QOL improvement rate of Intraperitoneal injection bevacizumab combined with Hyperthermic intraperitoneal chemotherapy group was also significantly higher than Hyperthermic intraperitoneal chemotherapy group [OR=6.49,95%CI(3.64~11.56),P<0.00001].No statistically significant differences were found in the incidence of white blood cell reduction[OR=1.08,95%CI(0.66~1.78)P=0.76],Thrombocytopenia [OR=1.17,95%CI(0.67~2.05),P=0.58],Hemoglobin reduce [OR= 1.18,95%CI(0.64~2.15),P=1.18],Nausea and vomiting [OR= 0.89,95%CI(0.55~1.42),P=0.62],Fatigue [OR= 0.79,95%CI(0.43~1.45),P=0.44],Pyrexia[OR= 1.35,95%CI(0.63~2.89),P=0.45],abdominal pain [OR= 0.89,95%CI(0.40~1.96),P=0.77],Abnormal liver function[ OR= 1.05,95%CI(0.54~2.04),P=0.88] and Alopecia [OR= 1.21,95%CI(0.6~2.44),P=0.6] in this meta-analysis.Conclusion: Intraperitoneal injection bevacizumab combined with Hyperthermic intraperitoneal chemotherapy can obviously increase the short-term curative effect and Improve the quality of life in the treatment of ovarian cancer.And it does not increase the risk of adverse reactions,it is reliable,security and feasible.